
CluePoints appoints three heads
pharmafile | March 4, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | cluepoints, colby, polvent, stephenne
Clinical trial data firm CluePoints has announced three new appointments to its global team.
John Colby (pictured) and Elizabeth Polvent join the company’s US business development team, while it also welcomes Jean Stéphenne, president of the board of directors of GSK Biologicals, as a member of its board.
Colby joins CluePoints as senior director of business development, providing strategic leadership and driving business growth. Previously Colby worked for Aptiv Solutions and PRA International.
Polvent has been named as the company’s director of business development. She has more than 10 years’ clinical operations experience in the industry with her most recent roles serving as the key liaison on Federally funded clinical trials, as well as overseeing early-phase clinical development programmes.
Stéphenne joined SmithKline-RIT (now GSK Biologicals) in 1974 as head of bacterial and viral vaccines production. Through various executive management positions within the company, he has led GSK’s global vaccines business since 1988.
From March 2010 to April 2012, he was appointed as the chairman and president of GSK Biologicals. Stéphenne currently serves as a special advisor to the chief executive at GSK.
Franҫois Torche, chief executive of CluePoints said: “I am delighted to announce the three new additions to our global team. I believe the insights and experience of each of these new appointments will be invaluable in our ongoing development.”






